drugset / Trial / NCT03067870

Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis

NCT03067870 ↗

Phase 1 Unknown 100 enrolled Stem Cells Arabia
NaSingle-groupOpen-labelTreatment

Summary

Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis ultimately results in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that autologous bone marrow-derived mesenchymal and specific populations of stem cells has anti-inflammatory and regenerative effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of BM-SC transplantation in treatment of rheumatoid arthritis.

Timeline

Start
2016-11
Primary completion
2021-12
Completion
2022-02

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow derived stem cells Cell therapy — Intravenous